DMG
0.011
83.3%
BLZ
0.001
-50%
RAN
0.003
50%
STP
0.3
-38.1%
FHS
0.004
33.3%
IPB
0.006
-33.3%
RFT
0.004
33.3%
VUL
4.1
-33.1%
RMY
0.048
33.3%
BOC
0.56
-29.1%
CKA
0.057
32.6%
RKB
0.003
-25%
WLD
0.017
30.8%
TGN
0.225
-25%
AVE
0.01
25%
N1H
0.135
-20.6%
CPO
0.015
25%
OVT
0.004
-20%
FBR
0.005
25%
PIL
0.004
-20%
OEL
0.005
25%
TYX
0.004
-20%
RLG
0.005
25%
PET
0.021
-19.2%
NSB
0.13
23.8%
BTE
0.053
-15.9%
AGN
0.27
22.7%
AIV
0.016
-15.8%
RR1
0.011
22.2%
DTR
0.24
-15.8%
PBL
0.089
21.9%
IMI
0.011
-15.4%
8IH
0.018
20%
BEL
0.017
-15%
APC
0.014
16.7%
NFM
0.017
-15%
CTT
0.815
15.6%
BNL
0.006
-14.3%
HWK
0.03
15.4%
ID8
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts